MIL •
Healthcare •
Biotechnology •
Quote as of 06/26/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeMIL
Market Capitalization54,820 mln
Float97.67 mln
Earnings Date07/31/2026
EPS
35.34
Exceptional
P / E
15.76
Moderately valued
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-2.56
Likely reliable
Relative Strength
88
/ 100
Strongly outperforming
Debt / Equity
0.09
Debt-free
Business Description
Regeneron Pharmaceuticals is a New York-based company that researches, develops, and sells treatments for a wide range of serious health conditions, including eye diseases, cancer, heart disease, and rare disorders. Its product lineup includes well-known medicines such as EYLEA, Dupixent, Libtayo, Praluent, and Kevzara, which are used by patients around the world. The company works alongside a number of partners, including Bayer, Alnylam, and Intellia Therapeutics, to advance new therapies in areas such as gene editing and RNA-based medicine. Founded in 1988, Regeneron continues to grow its pipeline through both internal discovery and strategic external collaborations.
